Amneal Plans Eight More ‘High Value’ Launches
Company Awaits FDA Approval For 91 Products
Based on its “solid track record of filing, getting approval and launching high-value generics,” Amneal not only plans to launch eight new “high value” products over the next year, the company also plans to file for another 20-25 generics. Amneal has 91 products in the pipeline awaiting FDA approval and 132 products actively in development, mainly in non-oral solid dosage forms.
You may also be interested in...
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.
Mayne Pharma has received a further setback in its attempt to bring a generic version of NuvaRing to the US market after the FDA issued the firm with another complete response letter.
As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.